TOP TEN perturbations for 39144_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39144_at
Selected probe(set): 211105_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39144_at (211105_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

DLBCL study 7 (plasmablast-like) / DLBCL study 7 (centroblast-like)

Relative Expression (log2-ratio):-4.4048805
Number of Samples:2 / 2
Experimental DLBCL study 7 (plasmablast-like)
Primary tumor samples from patients with unclassified diffuse large B-cell lymphoma. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to plasmablast-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.
Control DLBCL study 7 (centroblast-like)
Primary tumor samples from patients with unclassified diffuse large B-cell lymphoma. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to centroblast-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.

bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-3.7349129
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondrosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)

Relative Expression (log2-ratio):3.5161724
Number of Samples:2 / 3
Experimental esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted).

hair follicle keratinocyte study 1 (CD200-/CD49+) / hair follicle keratinocyte study 1 (CD200+/CD49+)

Relative Expression (log2-ratio):-3.205431
Number of Samples:3 / 3
Experimental hair follicle keratinocyte study 1 (CD200-/CD49+)
Primary hair follicle keratinocytes sample negative for CD200 and positive for CD49.
Control hair follicle keratinocyte study 1 (CD200+/CD49+)
Primary hair follicle keratinocytes sample positive for CD200 and CD49.

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-3.2047272
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):3.1519346
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-3.0144234
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

rapidly progressive glomerulonephritis; ANCA-associated vasculitis study 5 (tubulointerstitium) / focal segmental glomerulosclerosis study 9 (glomerulus)

Relative Expression (log2-ratio):-2.9874506
Number of Samples:21 / 10
Experimental rapidly progressive glomerulonephritis; ANCA-associated vasculitis study 5 (tubulointerstitium)
Tubulointerstitium tissue sample obtained by microdissection from kidney biopsy, from patients suffering from rapidly progressive glomerulonephritis and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Donors were positive for ANCA-antibody. Biopsy samples were obtained from the European Renal cDNA Bank-Kroener-Fresenius biopsy bank. All biopsies were stratified by a reference pathologist.
Control focal segmental glomerulosclerosis study 9 (glomerulus)
Glomeruli tissue sample obtained by microdissection from kidney biopsy, from patients suffering from focal segmental glomerulosclerosis. Biopsy samples were obtained from the European Renal cDNA Bank-Kroener-Fresenius biopsy bank. All biopsies were stratified by a reference pathologist.

CAR T cell study 4 (PSCA-28t28Z; pre-infusion) / CAR T cell study 4 (GFP; pre-infusion)

Relative Expression (log2-ratio):-2.9132137
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).
Control CAR T cell study 4 (GFP; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) / endometrial cancer study 1 (PDX; carcinosarcoma, NOS; primary)

Relative Expression (log2-ratio):2.755498
Number of Samples:3 / 10
Experimental endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinosarcoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control endometrial cancer study 1 (PDX; carcinosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary carcinosarcoma, NOS of the endometrium (subcutaneously implanted).